XV 459

Known as: XV-459, XV459 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1996-2007
02419962007

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Suppressing platelet activation improves efficacy of thrombolytic therapy for stroke and acute myocardial infarction. Combination… (More)
Is this relevant?
2003
2003
Roxifiban (DMP 754) is a glycoprotein (GP) IIb/IIIa antagonist. Following oral administration to humans, roxifiban is metabolized… (More)
Is this relevant?
2002
2002
Roxifiban is an esterprodrug that is hydrolyzed, after oral administration, to the active glycoprotein (GP) IIb/IIIa antagonist… (More)
Is this relevant?
2001
2001
Several platelet alpha(IIb)beta(3) integrin antagonists have been designed as preventive agents against the formation of arterial… (More)
Is this relevant?
2001
2001
The effect of various platelet glycoprotein IIb/IIIa (GPIIb/IIIa) antagonists on the dynamics of platelet-fibrin clot formation… (More)
Is this relevant?
2000
2000
In the present study, the in vitro efficacy of different platelet glycoprotein IIb/IIIa (GPIIb/IIIa) antagonists on platelet… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
1999
1999
Currently used antiplatelet drugs, including aspirin, ticlopidine, and others, are effective against certain but not all of the… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
1998
1998
The effects of the platelet alphaIIb beta3 integrin (GPIIb/IIIa) antagonists XV459 (non-peptide), c7E3 (Fab monoclonal antibody… (More)
Is this relevant?
1998
1998
Recent advances in the development of i.v. platelet glycoprotein alphaIIb/beta3 integrin (GPIIb/IIIa) antagonists led to the… (More)
  • figure 1
  • table 2
  • figure 2
  • table 3
  • table 1
Is this relevant?
1996
1996
OBJECTIVE To define the antiplatelet efficacy and specificity of the glycoprotein IIb/IIIa complex (GPIIb/IIIa) antagonist… (More)
Is this relevant?